A Trial of SAMe for Treatment-Resistant Bipolar Depression
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's
mechanism of action remains unclear, but it appears to be distinct from that of conventional
antidepressants. The purpose of this study is to examine the effect of these properties on
the mood of bipolar subjects with persistent major depression that has been unresponsive to
standard pharmacotherapy.